Windlas Biotech Limited

BSE: WINDLAS543329ISIN INE0H5O01029

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹873.45-6.30 (-0.72%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,181.00
52W low: ₹699.35
Off 52W high: -26.04%
1M return: -14.20%
3M return: +2.51%
6M return: +1.19%
1Y return: -6.62%
20D avg volume: 3,747
50 DMA: ₹1,012.18
200 DMA: ₹870.20

Key ratios Consolidated

Market cap: ₹1,849 Cr
Current price: ₹873.45
52W high / low: ₹1,181.00 / ₹699.35
Face value: ₹5.00
P/E: 27.12
P/B: 3.17
EPS (TTM): ₹32.20
Book value / share: ₹275.20
ROE: —
ROCE: 15.70%
Operating margin: —
Net margin: —
Debt / equity: 0.05
Net debt: ₹29.34 Cr
Interest cover: 19.01
Dividend yield: 0.72%
Dividend / share (TTM): ₹6.30
Payout: 19.57%
Cash conversion cycle: 20.5 days

Financials

Metric	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24
Income statement
	238.50	233.10	222.40	210.09	202.71	195.02	187.00	175.15	171.28	162.21	152.67	144.79
	4.35	4.57	3.65	5.24	4.94	4.11	4.84	4.13	4.44	3.16	3.24	2.62
	242.85	237.67	226.04	215.33	207.64	199.13	191.84	179.29	175.72	165.38	155.91	147.41
	222.69	217.70	202.46	192.07	186.82	178.79	171.56	160.97	153.09	145.57	137.60	131.07
	3.78	5.47	8.04	6.11	3.33	0.88	0.38	2.26	2.06	5.43	4.35	1.98
	141.68	140.40	136.25	119.35	111.77	133.64	127.17	118.48	104.55	105.34	86.45	87.29
	41.37	42.05	36.45	32.23	31.93	32.17	30.97	27.85	22.85	22.73	21.32	20.56
	1.48	1.28	1.02	1.06	1.33	1.46	1.10	0.49	0.28	0.30	0.28	0.24
	8.00	7.70	7.60	7.45	8.34	6.94	6.50	6.21	3.54	3.39	3.33	3.19
	24.79	23.18	20.45	21.61	20.04	2.77	2.40	2.18	5.11	1.86	2.26	—
	20.16	19.97	23.59	23.26	20.82	20.34	20.29	18.31	22.63	19.81	18.31	16.34
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	20.16	19.97	23.59	23.26	20.82	20.34	20.29	18.31	22.63	19.81	18.31	16.34
	4.17	4.97	5.79	5.59	4.54	4.76	4.63	4.83	5.64	4.71	4.28	4.28
	15.99	15.00	17.80	17.66	16.28	15.58	15.66	13.48	16.99	15.10	14.03	12.06
	7.58	7.12	8.48	8.43	7.77	7.45	7.49	6.47	8.17	7.26	6.75	5.79
Key metrics
	29.64	28.95	32.21	31.77	30.49	28.74	27.89	25.01	26.45	23.50	21.92	19.77
	12.40%	12.40%	14.50%	15.10%	15.00%	14.70%	14.90%	14.30%	15.40%	14.50%	14.40%	13.70%
	6.70%	6.40%	8.00%	8.40%	8.00%	8.00%	8.40%	7.70%	9.90%	9.30%	9.20%	8.30%
	3.70%	—	4.50%	—	4.30%	—	—	—	—	—	—	—
	17.70%	19.50%	18.90%	19.90%	18.40%	20.20%	22.50%	21.00%	—	—	—	—
	-1.80%	-3.70%	13.70%	31.00%	-4.20%	3.20%	11.60%	11.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	904.09	904.09	759.88	630.96	513.08	465.93
	17.81	17.80	18.02	13.47	9.96	6.71
	921.89	921.89	777.90	644.42	523.05	472.64
	834.92	834.92	698.14	567.33	466.01	427.07
	23.40	12.46	2.33	2.96	0.76	307.56
	537.68	537.67	491.05	383.63	341.48	—
	152.10	152.09	122.92	87.46	70.32	63.41
	4.84	4.83	4.38	1.10	0.79	1.42
	30.75	30.74	27.98	13.44	12.36	12.15
	90.03	90.02	71.00	11.74	—	8.23
	86.98	86.98	79.76	77.09	57.04	45.56
	0.00	0.00	0.00	0.00	0.00	0.00
	86.98	86.98	79.76	77.09	57.04	45.56
	20.52	20.52	18.76	18.90	14.41	7.48
	66.45	66.46	60.99	58.19	42.63	38.09
	31.61	31.60	29.19	27.97	19.70	18.58
Key metrics
	122.57	122.55	112.12	91.63	70.19	59.13
	13.56%	13.60%	14.80%	14.50%	13.70%	12.70%
	7.35%	7.40%	8.00%	9.20%	8.30%	8.20%
	—	15.70%	16.50%	—	—	—
	18.98%	19.00%	20.40%	23.00%	10.10%	—
	8.93%	9.00%	4.80%	36.50%	11.90%	—
	—	37.27	16.00	—	—	—
	—	1.58	1.12	—	—	—
	—	0.05	0.05	—	—	—
	—	29.34	26.70	—	—	—
	—	20.5	38.9	—	—	—
Balance sheet
	—	907.35	760.45	—	—	—
	—	626.85	525.13	—	—	—
	—	0.54	0.42	—	—	—
	—	227.40	166.86	—	—	—
	—	61.82	81.38	—	—	—
	—	57.84	33.31	—	—	—
	—	187.18	195.49	—	—	—
	—	238.49	167.24	—	—	—
	—	320.93	249.44	—	—	—
	—	29.88	27.12	—	—	—
	—	29.88	27.12	—	—	—
	—	0.00	0.00	—	—	—
	—	580.84	505.77	—	—	—
Cash flow
	—	104.93	68.19	—	—	—
	—	-91.79	-74.06	—	—	—
	—	-13.03	1.01	—	—	—
	—	67.66	52.19	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	248.10	238.50	233.10	222.40	210.09	202.71	195.02	187.00	175.15	171.28	162.21	152.67
	5.11	4.40	4.52	3.65	5.24	4.94	3.73	4.84	4.13	4.44	3.16	3.24
	253.21	242.90	237.62	226.04	215.33	207.65	198.75	191.84	179.29	175.72	165.38	155.91
	230.28	222.74	217.70	202.46	192.07	186.82	178.78	171.56	160.97	153.16	145.57	137.60
	-13.48	3.78	-5.47	8.04	6.11	3.33	0.88	0.38	2.26	2.06	5.43	4.35
	182.22	141.68	140.40	136.25	119.35	111.77	133.64	127.17	118.48	104.55	105.34	86.45
	44.43	41.37	42.05	36.45	32.23	31.93	32.17	30.97	27.85	22.85	22.73	21.32
	1.65	1.48	1.28	1.02	1.06	1.33	1.46	1.10	0.49	0.28	0.30	0.28
	7.21	8.00	7.70	7.60	7.45	8.34	6.94	6.50	6.21	3.54	3.39	3.33
	24.26	24.84	23.18	20.45	21.61	20.04	2.77	2.40	2.18	5.14	1.86	2.26
	22.94	20.16	19.92	23.59	23.26	20.83	19.97	20.29	18.31	22.56	19.81	18.31
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	22.94	20.16	19.92	23.59	23.26	20.83	19.97	20.29	18.31	22.56	19.81	18.31
	5.28	4.15	4.97	5.79	5.59	4.54	4.74	4.63	4.83	5.61	4.71	4.28
	17.65	16.02	14.95	17.80	17.66	16.29	15.23	15.66	13.48	16.95	15.10	14.03
	8.46	7.60	7.09	8.48	8.43	7.77	7.29	7.49	6.47	8.15	7.26	6.75
Key metrics
	31.80	29.64	28.90	32.21	31.77	30.50	28.37	27.89	25.01	26.38	23.50	21.92
	12.80%	12.40%	12.40%	14.50%	15.10%	15.00%	14.50%	14.90%	14.30%	15.40%	14.50%	14.40%
	7.10%	6.70%	6.40%	8.00%	8.40%	8.00%	7.80%	8.40%	7.70%	9.90%	9.30%	9.20%
	—	3.70%	—	4.50%	—	4.30%	—	—	—	—	—	—
	18.10%	17.70%	19.50%	18.90%	19.90%	18.40%	20.20%	22.50%	—	—	—	—
	-0.10%	-1.70%	-1.80%	13.70%	31.00%	-3.90%	0.90%	11.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	942.10	904.09	759.88	630.96	513.08	465.93
	17.68	17.80	17.65	13.47	9.96	6.71
	959.77	921.89	777.52	644.42	523.05	472.64
	873.18	834.96	698.13	567.40	465.99	426.60
	-7.13	12.46	2.33	2.96	0.76	307.56
	600.55	537.67	491.05	383.63	341.48	—
	164.30	152.09	122.92	87.46	70.32	63.41
	5.43	4.83	4.38	1.10	0.79	1.42
	30.51	30.74	27.98	13.44	12.36	12.15
	92.73	90.07	70.99	11.77	—	8.23
	86.61	86.93	79.39	77.02	57.06	46.04
	0.00	0.00	0.00	—	—	—
	86.61	86.93	79.39	77.02	57.06	46.04
	20.19	20.50	18.75	18.88	14.41	7.48
	66.42	66.44	60.65	58.14	42.64	38.56
	31.63	31.59	29.03	27.95	19.71	18.81
Key metrics
	122.55	122.50	111.75	91.56	70.21	59.61
	13.01%	13.50%	14.70%	14.50%	13.70%	12.80%
	7.05%	7.30%	8.00%	9.20%	8.30%	8.30%
	—	15.60%	16.40%	—	—	—
	18.53%	19.00%	20.40%	23.00%	10.10%	—
	2.44%	9.50%	4.30%	36.40%	10.60%	—
	—	37.27	16.04	—	—	—
	—	1.58	1.12	—	—	—
	—	0.05	0.05	—	—	—
	—	29.35	26.70	—	—	—
	—	20.5	38.9	—	—	—
Balance sheet
	—	907.34	760.45	—	—	—
	—	626.84	525.13	—	—	—
	—	0.53	0.42	—	—	—
	—	227.40	166.86	—	—	—
	—	61.82	81.38	—	—	—
	—	57.84	33.31	—	—	—
	—	187.18	195.49	—	—	—
	—	238.49	167.24	—	—	—
	—	320.93	249.42	—	—	—
	—	29.88	27.12	—	—	—
	—	29.88	27.12	—	—	—
	—	0.00	0.00	—	—	—
	—	580.83	505.79	—	—	—
Cash flow
	—	104.93	68.23	—	—	—
	—	-91.79	-74.06	—	—	—
	—	-13.03	1.01	—	—	—
	—	67.66	52.19	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +20.78%
Sales CAGR 5Y: —
Profit CAGR 3Y: +15.93%
Profit CAGR 5Y: —
Sales YoY (TTM): +18.53%
Profit YoY (TTM): +2.44%

Consolidated

Sales CAGR 3Y: +20.78%
Sales CAGR 5Y: —
Profit CAGR 3Y: +15.95%
Profit CAGR 5Y: —
Sales YoY (TTM): +18.98%
Profit YoY (TTM): +8.93%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 63.31%

Quarter	September 2026	June 2026
Promoter %	63.31%	63.31%

Holder	Type	Holding	Previous	Change
AKW WBL Family Private Trust (through its Trustees Ashok Vimla Trusteeship Services Private Limited)	Promoter	40.61%	40.61%	0.00%
Ashok Kumar Windlass	Promoter	21.32%	21.32%	0.00%
Icici Prudential Healthcare Fund	Public	1.73%	—	—
Mncl Capital Compounder Fund 2	Public	1.70%	1.70%	0.00%
Vimla Windlasss	Promoter Group	1.38%	1.38%	0.00%
Ajay Kumar Aggarwal	Public	1.21%	1.21%	0.00%
Perpetuity Health To Wealth (H2w) Rising Fund	Public	1.11%	1.11%	0.00%
Richa Mittal	Promoter Group	0.00%	0.00%	0.00%
Windlas Exports Private Limited	Promoter Group	0.00%	0.00%	0.00%
Windlas Foundation	Promoter Group	0.00%	0.00%	0.00%
Ayann Windlass	Promoter Group	0.00%	0.00%	0.00%
Hitesh Windlass	Promoter	0.00%	0.00%	0.00%
Ashok Vimla Trusteeship Services Private Limited	Promoter Group	0.00%	0.00%	0.00%
Manoj Kumar Windlass	Promoter	0.00%	0.00%	0.00%
Rhiditya Windlass	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Windlas Biotech Limited	1,849	873.45	27.12	15.70%	+18.98% TTM	+8.93% TTM	-6.62%

Filings & corporate actions

Recent announcements

Intimation of Cyber Security Incident30 Oct 2026 · Company Update / General
Schedule of Conference Call to discuss financial performance for quarter and half year ended September 30, 202630 Oct 2026 · Company Update / Analyst / Investor Meet
Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the un-audited standalone ....30 Oct 2026 · Board Meeting / Board Meeting
Resignation of Mr. Vivek Dhariwal (DIN: 02826679), Independent Director of the Company, with effect from close of business hours on October 12, 202613 Oct 2026 · Company Update / Change in Management
Intimation of change in the composition of the Board in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201512 Oct 2026 · Company Update / Change in Management
Appointment and Resignation of Directors12 Oct 2026 · Company Update / General
Certificate under Regulation 74 (5) of the SEBl (Depositories and Participants) Regulations, 2018 for the Quarter ended September 30, 20267 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 20151 Sep 2026 · Company Update / Analyst / Investor Meet
Q1 FY27 Earnings Conference Call Transcript enclosed.14 Aug 2026 · Company Update / Earnings Call Transcript
Audio Recording Q1 conference call11 Aug 2026 · Company Update / General
Press release titled 'Windlas Biotech Limited Reports its Q1 FY27 Financial Results'10 Aug 2026 · Company Update / Press Release / Media Release
Investor Presentation - Q1 FY27 enclosed10 Aug 2026 · Company Update / Investor Presentation
approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.10 Aug 2026 · Result / Financial Results
approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.10 Aug 2026 · Board Meeting / Outcome of Board Meeting
Schedule of Conference Call to discuss financial performance for quarter ended June 30, 20265 Aug 2026 · Company Update / Analyst / Investor Meet
Schedule of Conference Call to discuss financial performance for quarter ended June 30, 20265 Aug 2026 · Company Update / Analyst / Investor Meet
Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Notice is hereby given that ....4 Aug 2026 · Board Meeting / Board Meeting
Submission of Combined Voting Results and Scrutinizer's Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') ....24 Jul 2026 · AGM/EGM / AGM
Submission of Combined Voting Results and Scrutinizer's Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') ....24 Jul 2026 · AGM/EGM / AGM
Proceedings of 25th Annual General Meeting of the Company held on July 23, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201523 Jul 2026 · AGM/EGM / AGM
Certificate under Regulation 74 (5) of the SEBl (Depositories and Participants) Regulations, 2018 for the Quarter ended June 30, 202610 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 20159 Jul 2026 · Company Update / Analyst / Investor Meet
Newspaper Advertisement of completion of despatch of the Notice of 25th Annual General Meeting and Annual Report for the financial year 2025-20262 Jul 2026 · Company Update / Newspaper Publication
Intimation of record date/ cut-off date for the 25th AGM and evoting1 Jul 2026 · Company Update / General
Annual Report for FY261 Jul 2026 · Others / Reg. 34 (1) Annual Report
Notice of 25th AGM to be held on July 23, 20261 Jul 2026 · AGM/EGM / AGM
Notice of 25th AGM1 Jul 2026 · AGM/EGM / AGM
Intimation of cut-off date for evoting and dividend1 Jul 2026 · Corp. Action / Record Date
Newspaper Advertisement of 25th Annual General Meeting30 Jun 2026 · Company Update / Newspaper Publication
Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015- Credit Rating29 Jun 2026 · Company Update / Credit Rating
Intimation of Schedule of Analyst/Institutional Investor Meetings26 Jun 2026 · Company Update / Analyst / Investor Meet
Intimation of Closure of Trading Window25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 201524 Jun 2026 · Company Update / Analyst / Investor Meet
Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 201524 Jun 2026 · Company Update / Analyst / Investor Meet
Q4 & FY26 Earnings Conference Call Transcript28 May 2026 · Company Update / Earnings Call Transcript
Annual Secretarial Compliance Report for the financial year ended March 31, 202626 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Audio recording of Investors/ Analyst conference call on the audited consolidated and standalone financial results of the Company for the quarter and financial year ended March 31, 2026,.22 May 2026 · Company Update / General
Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 regarding grant of Stock Options/ Units under 'WBL Employee Stock Option ....21 May 2026 · Company Update / General
'Windlas Biotech Limited Reports its Q4 and FY26 Financial Results'21 May 2026 · Company Update / Press Release / Media Release

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 6.3000	16 Jul 2026	16 Jul 2026	—
Buy Back of Shares	24 Apr 2026	24 Apr 2026	—
Final Dividend - Rs. - 5.8000	21 Jul 2025	21 Jul 2025	—
Dividend - Rs. - 5.5000	17 Sep 2024	—	—

Board meetings

5 Nov 2026 Board Meeting - Financial Results
10 Aug 2026 Board Meeting - Financial Results